NCT03637322

Brief Summary

This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and continue taking PrEP will be examined.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
42

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Jun 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 27, 2018

Completed
3 months until next milestone

Study Start

First participant enrolled

June 1, 2018

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 20, 2018

Completed
4.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

March 31, 2023

Status Verified

March 1, 2023

Enrollment Period

4.6 years

First QC Date

February 27, 2018

Last Update Submit

March 30, 2023

Conditions

Outcome Measures

Primary Outcomes (1)

  • PrEP Uptake

    Uptake of PrEP offered to youth presenting for PrEP ages 13-24

    3 years

Eligibility Criteria

Age13 Years - 24 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Youth aged 13 through 24 in the Phoenix area who are high risk for HIV infections because of unsafe sex practices and or IV drug use and have been offered PrEP as part of their standard medical care.

You may qualify if:

  • sexually active youth aged 13 through 24,
  • at risk for contracting HIV,
  • Negative for HIV as indicated by Negative Elisa and Western Blot (WB) or Negative 4th Generation test,
  • weight greater than 35kg,
  • offered PrEP to reduce the risk of contracting HIV.

You may not qualify if:

  • Unknown or Positive HIV status,
  • Renal Impairment as indicated by elevated BUN or Creatinine, abnormal urinalysis,
  • Active infection with Hepatitis B Virus,
  • Taking other medications containing Emtricitabine, Tenofovir or tenofovir alafenamide(TAF) such as Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, and Viread taking drugs containing lamivudine,
  • taking Hepsera,
  • clinical symptoms consistent with acute viral infection within the past month.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Phoenix Children's Hospital, Bill Holt Clinic

Phoenix, Arizona, 85044, United States

Location

MeSH Terms

Conditions

Unsafe Sex

Condition Hierarchy (Ancestors)

Sexual BehaviorBehavior

Study Officials

  • Janice Piatt, MD

    Phoenix Children's Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 27, 2018

First Posted

August 20, 2018

Study Start

June 1, 2018

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

March 31, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations